A clinical-stage biopharma firm advancing proprietary treatments for metabolic conditions and chronic pain with a strong cash position relative to current liabilities.
Investors may be attracted to Supernus for its strategic positioning in the booming obesity and metabolic disease markets with a diverse portfolio of clinical assets. The company's ability to generate reported earnings while managing a healthy cash balance suggests effective capital allocation and potential for value creation if key drugs secure regulatory approval.
The significant cash outflow from investing activities and massive marketable security purchases indicate a lack of tangible asset growth or traditional operational scaling, which is typical but risky for a company with such high administrative burn. Investors should exercise caution due to the substantial retained earnings deficit of $556.4M, suggesting that current profits are not yet sufficient to cover historical losses without external financing.
Supernus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic disorders, pain management, and rare diseases. With significant investments in research and development exceeding $108 million recently, the company targets unmet medical needs through innovative drug candidates primarily intended for the US market.
Despite reporting a net profit of $73.9M, the company's cash flow from operations was significantly lower than earnings due to heavy non-cash adjustments and large mark-to-market losses on available-for-sale securities totaling $688M in purchases. The substantial increase in accounts receivable by $142.1M compared to payables suggests aggressive revenue recognition or potential collection challenges, while the massive cash outflow from investing activities indicates heavy capital deployment into marketable securities rather than traditional fixed asset growth.
The pharmaceutical industry is currently experiencing a surge in demand for treatments addressing obesity and chronic pain, sectors where Supernus aims to capitalize with its specialized drug candidates. However, the sector remains highly competitive with stringent regulatory environments requiring billions in investment before any product achieves commercial success.
| Metric | 2022 | 2024 |
|---|---|---|
| Revenue | $667.2M | $661.8M |
| Cost of Revenue | $87.2M | $77.9M |
| Gross Profit | $580.0M | $583.9M |
| Operating Expenses | $533.9M | $502.2M |
| Operating Income | $46.1M | $81.7M |
| R&D | $74.6M | $108.8M |
| G&A | $377.2M | $321.6M |
| Stock-Based Comp | $17.6M | $27.8M |
| D&A | $85.5M | $80.4M |
| Amortization | $82.6M | $78.0M |
| Other OpEx | $82.1M | $71.9M |
| Non-Operating Income | $14.6M | $16.2M |
| Pre-Tax Income | $60.7M | $97.9M |
| Income Tax | $32.0K | $24.0M |
| Continuing Ops | $60.7M | $73.9M |
| Discontinued Ops | $0 | $0 |
| Net Income | $60.7M | $73.9M |
| Minority Interest | $0 | $0 |
| Net to Common | $60.7M | $73.9M |
| Metric | 2022 | 2024 |
|---|---|---|
| Current Assets | $734.2M | $686.1M |
| Cash & Equivalents | $93.1M | $69.3M |
| Marketable Securities | $368.2M | — |
| Accounts Receivable | $165.5M | $142.1M |
| Inventory | $91.5M | $54.3M |
| Prepaid Expenses | $15.8M | $36.1M |
| Other Current Assets | $0 | $384.3M |
| Long-Term Assets | $968.4M | $682.0M |
| PP&E (Net) | $15.2M | $11.5M |
| Intangibles | $702.5M | $521.9M |
| Goodwill | $117.0M | $117.0M |
| Operating Leases | $28.9M | $24.5M |
| LT Securities | $93.9M | — |
| Other LT Assets | $10.9M | $7.0M |
| Total Assets | $1.70B | $1.37B |
| Current Liabilities | $688.0M | $292.4M |
| Accounts Payable | $10.5M | $4.6M |
| Current Leases | $6.8M | $6.9M |
| Other Current Liab | $574.3M | $204.6M |
| Long-Term Liabilities | $128.3M | $39.9M |
| LT Operating Leases | $36.0M | $27.4M |
| Other LT Liab | $92.3M | $12.6M |
| Total Liabilities | $816.3M | $332.3M |
| Shareholders' Equity | $886.2M | $1.04B |
| Paid-In Capital | $408.1M | $479.4M |
| Retained Earnings | $481.2M | $556.4M |
| AOCI | $-3.2M | $-189.0K |
| Total L&E | $1.70B | $1.37B |
| Metric | 2022 | 2024 |
|---|---|---|
| Net Income (CFO) | $60.7M | $73.9M |
| Non-Cash Adjustments | $41.1M | $111.6M |
| Working Capital Changes | $15.1M | $-13.5M |
| Cash from Operations | $116.8M | $172.0M |
| Capital Expenditures | — | $725.0K |
| Cash from Investing | $-216.7M | $-189.9M |
| Cash from Financing | $-10.5M | $12.2M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-110.3M | $-5.7M |
| Beginning Cash | $203.4M | $75.1M |
| Ending Cash | $93.1M | $69.3M |
The company's revenue structure is driven by its pipeline of investigational drugs targeting metabolic diseases such as obesity and diabetes, alongside indications in pain management and rare genetic disorders. Recent financials suggest a heavy reliance on research grants or strategic collaborations given the high operating expenses and significant non-cash adjustments typical of pre-commercial biotech entities.
As a clinical-stage company, Supernus faces substantial uncertainty regarding the success of its drug candidates in reaching approval and generating commercial revenue. The high level of operating expenses, particularly general and administrative costs at $321.6M, poses a risk to cash reserves if sales do not materialize quickly. Regulatory hurdles in the pharmaceutical sector could delay or prevent market entry for key product candidates.
Supernus leverages a robust pipeline of proprietary assets with distinct mechanisms of action in high-value therapeutic areas like obesity and pain, creating potential for first-in-class breakthroughs. The company maintains a strong balance sheet with $69.3M in cash and equivalents, providing essential runway to fund expensive R&D without immediate pressure for profitability.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.